Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms.
(2011) In Maturitas 70(4). p.373-378- Abstract
- OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among... (More)
- OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among women with intense VMS, ever HT use borderline significantly decreased CHD risk compared with never HT use (HR 0.48 [95% CI 0.20-1.03]). Among women without intense VMS, ever HT use was associated with a borderline significant increased CHD risk (HR 1.28 [95% CI 0.96-1.70]; P for interaction=0.02). However, after multivariate adjustment, as compared to never HT use, ever HT use was not associated with risk of CHD among women with or without intense VMS. CONCLUSIONS: In both groups of women with and without VMS, HT use does not seem to be associated with the risk of CHD. Hence, our findings do not support the view that HT use increases the CHD risk among women with an indication, i.e. VMS, but this needs to be confirmed in specifically designed studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2200760
- author
- Gast, Gerrie-Cor M ; Pop, Victor J M ; Samsioe, Göran LU ; Grobbee, Diederick E ; Nilsson, Peter M LU ; Keyzer, Jules J ; Wijnands-van Gent, Colette J M and van der Schouw, Yvonne T
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Maturitas
- volume
- 70
- issue
- 4
- pages
- 373 - 378
- publisher
- Elsevier
- external identifiers
-
- wos:000297882600012
- pmid:21978631
- scopus:80755133718
- pmid:21978631
- ISSN
- 1873-4111
- DOI
- 10.1016/j.maturitas.2011.09.005
- language
- English
- LU publication?
- yes
- id
- 167a2e0c-f9a7-4054-9a74-b414f422e3d7 (old id 2200760)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21978631?dopt=Abstract
- date added to LUP
- 2016-04-01 10:15:09
- date last changed
- 2024-02-14 13:36:04
@article{167a2e0c-f9a7-4054-9a74-b414f422e3d7,
abstract = {{OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among women with intense VMS, ever HT use borderline significantly decreased CHD risk compared with never HT use (HR 0.48 [95% CI 0.20-1.03]). Among women without intense VMS, ever HT use was associated with a borderline significant increased CHD risk (HR 1.28 [95% CI 0.96-1.70]; P for interaction=0.02). However, after multivariate adjustment, as compared to never HT use, ever HT use was not associated with risk of CHD among women with or without intense VMS. CONCLUSIONS: In both groups of women with and without VMS, HT use does not seem to be associated with the risk of CHD. Hence, our findings do not support the view that HT use increases the CHD risk among women with an indication, i.e. VMS, but this needs to be confirmed in specifically designed studies.}},
author = {{Gast, Gerrie-Cor M and Pop, Victor J M and Samsioe, Göran and Grobbee, Diederick E and Nilsson, Peter M and Keyzer, Jules J and Wijnands-van Gent, Colette J M and van der Schouw, Yvonne T}},
issn = {{1873-4111}},
language = {{eng}},
number = {{4}},
pages = {{373--378}},
publisher = {{Elsevier}},
series = {{Maturitas}},
title = {{Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms.}},
url = {{https://lup.lub.lu.se/search/files/1689897/2255829.pdf}},
doi = {{10.1016/j.maturitas.2011.09.005}},
volume = {{70}},
year = {{2011}},
}